PLEKHA6 and prostate cancer: We also detected moderate membranous staining along with variable intensity of cytoplasmic staining with TPM3 and PLEKHA6 fusion partners and perinuclear staining with LMNA. IRF2BP2::NTRK1 fusion represents only 2% of all NTRK fusions [7], but it has been reported in lung, thyroid and prostate cancers [3].